Health Care & Life Sciences » Pharmaceuticals | Jiangxi Fushine Pharmaceutical Co. Ltd.

Jiangxi Fushine Pharmaceutical Co. Ltd. A | Income Statement

Fiscal year is January-December. All values CNY Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
441,407.40
509,453.00
577,559.80
756,588.60
948,967.20
1,151
Cost of Goods Sold (COGS) incl. D&A
332,963.70
376,444.90
380,933.80
445,119.20
602,250.60
751
Gross Income
108,443.70
133,008.00
196,626.00
311,469.40
346,716.60
400
SG&A Expense
49,678.90
62,361.50
77,429.70
126,172.90
136,376.40
150
EBIT
58,172.50
69,328.60
116,203.70
184,300.40
210,340.20
251
Unusual Expense
13.20
-
-
-
114.10
14
Non Operating Income/Expense
2,864.60
844.10
388.80
4,370.00
15,090.50
8
Interest Expense
9,453.20
10,429.20
12,213.30
8,582.80
15,769.40
24
Pretax Income
52,925.80
63,602.40
111,584.80
203,629.40
201,053.00
234
Income Tax
7,853.20
10,161.10
17,983.10
31,109.20
26,576.30
35
Consolidated Net Income
45,072.70
53,441.20
93,601.80
172,520.20
174,476.70
192
Net Income
45,072.70
53,441.20
93,601.80
173,909.40
177,550.40
195
Net Income After Extraordinaries
45,072.70
53,441.20
93,601.80
173,909.40
177,550.40
195
Net Income Available to Common
45,072.70
53,441.20
93,601.80
173,909.40
177,550.40
195
EPS (Basic)
0.21
0.25
0.58
0.81
0.79
0.72
Basic Shares Outstanding
215,999.90
215,999.90
162,315.10
216,036.60
224,620.50
270
EPS (Diluted)
0.21
0.25
0.58
0.79
0.79
0.72
Diluted Shares Outstanding
215,999.90
215,999.90
162,315.10
220,138.50
224,747.30
270
EBITDA
73,908.50
89,797.70
144,886.90
218,723.30
256,067.40
305
Other Operating Expense
592.30
1,317.90
2,992.60
996.20
-
1
Non-Operating Interest Income
666.90
1,038.30
1,330.10
3,734.20
13,267.90
11
Minority Interest Expense
-
-
-
1,389.20
3,073.70
2

About Jiangxi Fushine Pharmaceutical Co.

View Profile
Address
Junction of Yushan & Liyang
Jingdezhen Jiangxi 333000
China
Employees -
Website http://www.fushine.cn
Updated 07/08/2019
Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of active pharmaceutical ingredient (API) and pharmaceutical intermediates. It focuses on penicillin and its API and intermediates, and carbapenem and its API and intermediates. The company was founded in December 2002 and is headquartered in Jingdezhen, China.